Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMT503 in Healthy Subjects
NCT05659953Phase 1Not yet recruiting
- Sponsor
- Lmito Therapeutics
- Start
- Mar 2027
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease comparing LMT503 with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at Day 17. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
LMT503
03
Conditions
inflammatory bowel disease (IBD)ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT05659953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659953.